Note: Ingredients listed on restricted chemical lists
EC/CAS
208-704-1/538-75-0
Name of the chemical
Dicyclohexylcarbodiimide
Concentration
<= 100 %
General Information
Product name
N,N-Dicyclohexyl Carbodiimide
CAS No.
538-75-0
1.2.1 Relevant identified uses
Laboratory chemicals, Industrial & for professional use only
Emergency telephone
+91 99921 51495
Icons in SDS
Company Information
company name
Bio-Chem Chemicals
e-mail address of the competent person responsible for the Safety Data Sheet
info@biofinechemical.com
GHS Information
Signal word
Danger
Hazard Codes
Hazard statements (CLP)
H302, H311, H317, H318
Hazard statements
Code
Statements
H302
Harmful if swallowed
Section 2
SECTION 2: Hazards identification
Regulation (EC) No. 1272/2008] Classification of the substance or mixture
Signal word
Danger
Hazard statements
H302 Harmful if swallowed. H311 Toxic in contact with skin. H317 May cause an allergic skin reaction. H318 Causes serious eye damage.
Precautionary statements
P280 W ear eye protection/ face protection. P280 W ear protective gloves/ protective clothing. P301 + P312 + P330 IF SW ALLOW ED: Call a POISON CENTER/doctor if you feel unwell. Rinse mouth. P302 + P352 + P312 IF ON SKIN: W ash with plenty of water.Call a POISON CENTER/doctor if you feel unwell. P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER/doctor.
Supplemental label elements
none
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher
2.1 Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 Acute toxicity, Oral (Category 4), H302 Acute toxicity, Dermal (Category 3), H311 Serious eye damage (Category 1), H318 Skin sensitisation (Category 1), H317 For the full text of the H-Statements mentioned in this Section, see Section 16.
